ACLX

ARCELLX, INC.

About ACLX

Arcellx Inc. is a clinical-stage biotechnology company. The Company is focused developing controllable cell therapies for the treatment of patients with cancer and other incurable diseases. The Company is advancing its CART-ddBCMA product through its iMMagine Phase 2 pivotal trial in patients with relapsed or refractory (r/r) multiple myeloma (MM). The Company is also advancing ARC-SparX programs, ACLX-001 in r/r MM and ACLX-002 and ACLX-003 in r/r acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). ARC-SparX are adaptable versions of ddCARs where the antigen-targeting region is located on a SparX protein that can be dosed separately from the ARC-T cells, its D-Domain based universal CAR-T cells that are designed to activate only when bound to a SparX protein that is bound to an antigen on a cell. It is also exploring indications in solid tumors.

Buy US stocks in Australia starting with ACLX. Open an account and start investing today!

Market Capitalisation

$1.25B

Price-earnings ratio

Dividend yield

0.00%

Volume

58K

High today

$29.70

Low today

$28.51

Open price

$28.92

52-week high

$35.26

52-week low

$6.04

ACLX FAQs

How much is one share of ARCELLX, INC.?

One share of ARCELLX, INC. is valued at $29.27.

What is the ticker symbol for ARCELLX, INC.?

The ticker symbol for ARCELLX, INC. is ACLX.

How do I buy ACLX shares in Australia?

To buy ACLX stocks in Australia you'll need to open an account with a broker like Stake.
To do so follow these steps:

Sign up in minutes, all you need is some I.D.
Choose Stake Wall St
Deposit directly into your Stake wallet and you're ready to invest in ACLX

What is the 52-week high for ARCELLX, INC. stock?

The ARCELLX, INC. 52-week high stock price is $35.26.

What is the 52-week low for ARCELLX, INC. stock?

The ARCELLX, INC. 52-week low stock price is $6.04.

What is the market capitalisation of ARCELLX, INC. ACLX?

As of 23/03/2023 ARCELLX, INC. has a market cap of $1.2B.

Related Stocks

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.